TQB2102, a novel HER2 bispecific ADC, combined with bemotrizumab with or without capecitabine as 1L for HER2+ GC/GEJC: A phase II study

Arndt Vogel· @ArndtVogel · X·2026-10-23 22:32· 2 days agoScore70

Body

TQB2102, a novel HER2 bispecific ADC, combined with bemotrizumab with or without capecitabine as 1L for HER2+ GC/GEJC: A phase II study
#ESMO26 #ESMOAmbassadors
👉 ORR: 69 vs 84% DCR 9
👉 mPFS: 12.7 vs 11.04 mo
🧐Supports combining CTx, ICI & Her2🎯 in 1L
@myESMO @ASCO

352 views · 4 likes · 2 reposts · 0 replies

Conference abstracts

2876ROmatched by Rapid oral 1: Gastrointestinal tumour, upper digestive

TQB2102, a novel HER2 bispecific antibody-drug conjugate, combined with bemotrizumab with or without capecitabine as first-line therapy for HER2-positive advanced gastric/gastroesophageal junction cancer: A phase II study

https://esmocongress.esmo.org

Source: Arndt Vogel · x.com